This content is only available within our institutional offering.
05 Mar 2019
Rude Health - finnCap Life Sciences quarterly sector note
Bioventix Plc (BVXP:LON), 4,450 | Byotrol plc (BYOT:LON), 0.4 | Inspiration Healthcare Group PLC (IHC:LON), 28.5 | Cambridge Nutritional Sciences PLC (CNSL:LON), 3.6 | OptiBiotix Health PLC (OPTI:LON), 21.0 | SDI Group plc (SDI:LON), 62.5 | Synairgen plc (SNG:LON), 5.1 | Tristel Plc (TSTL:LON), 448
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
Rude Health - finnCap Life Sciences quarterly sector note
Bioventix Plc (BVXP:LON), 4,450 | Byotrol plc (BYOT:LON), 0.4 | Inspiration Healthcare Group PLC (IHC:LON), 28.5 | Cambridge Nutritional Sciences PLC (CNSL:LON), 3.6 | OptiBiotix Health PLC (OPTI:LON), 21.0 | SDI Group plc (SDI:LON), 62.5 | Synairgen plc (SNG:LON), 5.1 | Tristel Plc (TSTL:LON), 448
- Published:
05 Mar 2019 -
Author:
Mark Brewer -
Pages:
32
AIM Healthcare Index is up 10% year to date, outperforming the AIM All Share (+6%) and FT All Share (+7%), having suffered with the broader market pull back in Q4 2018, in which AIM Healthcare fell 18%. This compared with a 22% decline in the AIM All Share and 11% decline in the FT All Share. In the past quarter, the AIM Health sector has fallen 1%, not helped by the FDA’s rejection of Motif Bio’s NDA for iclaprim. However, there were 14 finnLife 50 stocks that exhibited double-digit percentage increases, most notable of which are Futura Medica (+112%), Avacta* (+82%), OptiBiotix* (+35%), hVIVO (+34%), Instem (+34%) and ANGLE* (+29%) in the past three months